A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 17 Mar 2026
At a glance
- Drugs CMS D001 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Dermavon
Most Recent Events
- 17 Mar 2026 New trial record